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Objectives. Lactoferrin is an iron-binding protein that is released from activated neutrophils at sites of inflammation and has anti-microbial as
well as anti-inflammatory properties. This study set out to determine whether lactoferrin can delay neutrophil apoptosis and could act as
a survival factor for neutrophils in SF.
Methods. Human peripheral blood and SF neutrophils were incubated with iron-free lactoferrin and apoptosis determined after 9h. SF from
patients with RA was added to isolated neutrophils, with or without immunodepletion of lactoferrin, and effects on neutrophil apoptosis
determined. Levels of lactoferrin in SF were assessed and related to disease duration and markers of disease activity.
Results. Iron-free lactoferrin significantly delayed apoptosis of peripheral blood neutrophils, in a concentration-dependent manner after 9h
in culture (P<0.04). Lactoferrin could also delay apoptosis of neutrophils isolated from SF of patients with RA. SF from patients with
established RA delayed apoptosis of peripheral blood neutrophils and this effect was significantly reduced by depletion of lactoferrin (P<0.03).
Lactoferrin levels in SF from patients with established RA did not correlate with disease severity, but did correlate with markers of inflammation
(CRP) and with the presence of RF. SF from patients with arthritis of <12 weeks duration did not contain significant levels of lactoferrin.
Conclusion. Lactoferrin contributes to extended neutrophil survival in the rheumatoid joint in the established phase of RA but not in very
early arthritis.
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Introduction
Neutrophils are the most abundant yet the most short-lived of
leucocytes, surviving for 24–48h in the circulation before dying
by apoptosis [1, 2]. Neutrophil apoptosis can be delayed at sites
of infection in order to maximize neutrophil bactericidal func-
tion [3], but inappropriate extension of neutrophil survival can
lead to chronic inflammation and pathology [4]. Tight regulation
of neutrophil apoptosis is thus required to prevent chronic
inflammatory diseases such as RA. We have shown previously
that neutrophil apoptosis is suppressed in the SF of patients with
established RA [5] and more recently also in those patients with
disease of <3 months duration [6], contributing significantly to the
persistence of inflammation. Several synovial components have
already been identified as neutrophil survival factors, including
type 1 IFN, GM-CSF and immune complexes [7–10]. The hypoxic
environment of the synovium has also been proposed as a factor
promoting neutrophil survival [11]. Identification of key micro-
environmental influences on neutrophil life span within the
inflamed joint may suggest further targets for therapy.
We and others have previously reported the importance of
reactive oxygen species as mediators of neutrophil spontaneous
apoptosis [12–14]. Neutrophils from patients with chronic granu-
lomatous disease, a hereditary defect in reactive oxygen interme-
diate (ROI) production, show significant inhibition of apoptosis
[12]. Mice that are hypomorphic for expression of the p47
phox
subunit of NADPH oxidase and show a minimal neutrophil
superoxide burst are highly sensitive to pristane-induced arthritis
[15]. Here we have investigated the role of the iron-binding protein
lactoferrin in regulating neutrophil apoptosis in the synovial
environment. Several iron chelators, including desferrioxamine
(DFO) have been shown to delay neutrophil spontaneous
apoptosis in vitro [13, 14, 16] and the physiological iron chelator
lactoferrin is often present at significant levels in SF [17–19].
Lactoferrin is an iron-binding glycoprotein belonging to the
transferrin family and is present in secondary granules in
neutrophils and milk and is released upon neutrophil activation
[20–22]. The concentration of lactoferrin in blood is normally low,
i.e. 0.2–0.6 g/ml, but at sites of inflammation this is significantly
raised due to its release from neutrophils and can be as high as
200 g/ml [23]. The effect of increased lactoferrin in the synovium
has been thought to be primarily anti-inflammatory. Iron
accumulates within the RA synovium and synovial macrophages
release hydrogen peroxide and superoxide, which can then be
converted to damaging hydroxyl radicals by free iron via the
Fenton/Haber-Weiss reaction. Iron chelation by lactoferrin will
thus remove a source of damaging ROI and indeed iron chelators,
including lactoferrin, have been shown to reduce inflammation
in animal models of inflammation, particularly septic arthritis [24]
and in patients with acute inflammation [25]. However, if synovial
lactoferrin also delays neutrophil apoptosis, it may have both
pro-inflammatory and anti-inflammatory effects within the
rheumatoid joint. Lactoferrin has been reported to have pro-
inflammatory effects by enhancing neutrophil adhesion [26].
Although an increased level of lactoferrin in SF of patients with
RA has been reported [17], no study has ever looked at its role in
regulating neutrophil apoptosis, though several studies have
shown that it has an anti-oxidant effect on these cells [27, 28].
As lactoferrin has been proposed as a possible therapy for RA
[24], we felt it important to determine if it could delay neutrophil
apoptosis. Our data show that lactoferrin was able to extend
neutrophil life-span and that depletion of lactoferrin from SF
reduced its ability to delay neutrophil apoptosis. Our results
suggest that lactoferrin may not be a useful anti-inflammatory in
all patients and perhaps its utility will be limited to those with
excessive accumulation of iron within the joint or with septic
arthritis in which extending neutrophil lifespan and function
would be beneficial.
Methods
Isolation and culture of human neutrophils
Neutrophils were isolated from the peripheral blood of healthy
volunteers as previously described [29] and all subjects gave their
written informed consent. Briefly, blood was collected into tubes
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T-500 in normal saline. Neutrophils were isolated using a discon-
tinuous density gradient of Percoll (Sigma-Aldrich, Poole, UK).
After hypotonic lysis to eliminate any remaining erythrocytes,
neutrophils were resuspended in a round-bottom polypropylene
tube in RPMI 1640 medium (Sigma-Aldrich) supplemented with
10% heat-inactivated fetal bovine serum (Sera Laboratories
International, Bolney, UK) and containing 2mM glutamine,
100U/ml penicillin and 100 ug/ml streptomycin (Sigma-Aldrich).
The purity of isolated neutrophils was determined by Giemsa
staining (Diff-Quick, Gamidor Technical Services, Didcot, UK),
and light microscopy and was routinely >97%, with eosinophils
as the main contaminating cell. For isolation of neutrophils from
SF, the synovial sample was treated with 10U/ml hyaluronidase
for 20min to reduce viscosity and then applied directly to the
Percoll density gradient. Purity was routinely >98%.
Neutrophils were cultured in a humidified atmosphere under
routine tissue culture conditions (5% CO2;  20% pO2), in the
presence or absence of a range of concentrations of iron-free
lactoferrin isolated from human milk (tissue culture grade, Sigma-
Aldrich). Lactoferrin interferes with routine assays for endotoxins
and for this reason all lactoferrin treatments also included
10 g/ml polymyxin B (Sigma-Aldrich) to neutralize lipopoly-
saccharide (LPS) and ensure that any effects were not due to
endotoxin contamination [30]. Neutrophils were also cultured
with other factors known to delay their apoptosis, namely
recombinant human GM-CSF (50ng/ml) and IFN- 
(800IU/ml), both purchased from R&D Systems, Abingdon,
UK, and LPS (Sigma-Aldrich).
SF
SF was collected from the joints of patients with established RA of
>2 yrs duration, or from patients attending a very early arthritis
clinic whose arthritis was of <3months duration. These latter
patients were followed to determine which ones went on to
develop RA. All patients gave their written informed consent to
their involvement in the study and the study was approved by
South Birmingham Local Research Ethics Committee (Study
Reference number LREC 04/Q2709/103). For immunodepletion
of lactoferrin, SF was incubated with an anti-lactoferrin mono-
clonal antibody (Sigma-Aldrich) or an isotype matched control
and the antibody removed using protein G linked to magnetic
beads (m beads, Miltenyi Biotec, Surrey, UK). The efficiency of
depletion was confirmed by ELISA and any remaining lactoferrin
was below the detection limit of the kit at 1ng/ml.
Measurement of neutrophil apoptosis
To determine the effect of various treatments on spontaneous
neutrophil apoptosis cytospin preparations (5min, 300rpm;
Cytospin 2; Shandon, Pittsburgh, PA, USA) were made and dif-
ferentially stained using a Giemsa stain and assessed for the classic
apoptotic morphology of condensed nucleus, reduced cytoplasm
and vacuolation [31]. Morphological assessments were confirmed
by measurement of mitochondrial permeability transition using
DiOC6 (Molecular Probes Inc., Leiden, The Netherlands) staining
and flow cytometric analysis as described previously [32].
For experiments involving incubation of neutrophils with SF,
apoptosis was determined by active caspase-3 staining and flow
cytometry. Briefly, neutrophils were fixed and permeabilized using
PermeaFix
TM solution (Ortho Diagnostic Systems Inc., Raritan,
NJ, US) for 45min at room temperature. The fixed cells were
washed twice in PBS/2% BSA (Sigma-Aldrich) and stained with
an affinity-purified rabbit anti-human active caspase-3 mAb (BD
Pharmingen, Oxford, UK) or normal rabbit immunoglobulin
fraction (DakoCytomation, Ely, UK) as a negative control.
Staining was detected with a FITC-conjugated goat anti-rabbit
IgG antibody (Cambridge Bioscience, Cambridge, UK) and flow
cytometry.
Measurement of neutrophil respiratory burst
Neutrophil respiratory burst in response to fMLP was determined
in neutrophils incubated for 20h in medium alone or in the
presence of lactoferrin. Generation of superoxide was measured in
a lucigenin-based assay as described previously [33] and results are
expressed as integral counts per minute, determined from the area
under the curve of the reaction for the first 10min and adjusted
for cell viability.
Measurement of lactoferrin in SF and serum
Lactoferrin was detected in serum and SF by ELISA, with paired
capture and biotinylated detection monoclonal antibody, using
a commercial kit (Calbiochem, Nottingham, UK). The lower limit
of detection was <1ng/ml. To block interference by RFs with the
lactoferrin ELISA, blocking with 40% mouse serum (Sigma-
Aldrich), 20% goat serum, 20% rabbit serum (DakoCytomation)
and 20% sample diluting buffer was used [33].
Statistical analysis
Data were analysed by Spearman’s correlation, Student’s t-test
or ANOVA followed by Dunnett’s comparison with control, as
appropriate. A P-value of <0.05 was considered to indicate
a significant difference between groups.
Results
Lactoferrin levels in SF
Lactoferrin was measured by ELISA in SFs aspirated from the
joints of 26 patients with RA of >2yrs duration and in matched
sera from 11 patients (Fig. 1). Levels in SF varied greatly, ranging
from 0.48 to 65.8 g/ml (mean 17.7 19.2 g/ml) and were in
broad agreement with previous reports for levels of lactoferrin in
SF [23]. Levels of lactoferrin in serum from patients with
established RA were very low (mean 1.5 0.5 g/ml), indicating
that lactoferrin was produced within the synovial environment,
again in agreement with previous reports [17]. We also measured
lactoferrin in SF taken from the articular joints of 10 patients
with an arthritis of <3 months disease duration who went on to
develop RA. We have shown recently that neutrophil apoptosis
was also delayed in the SF of these patients [6], despite the
different cytokine content of the aspirate compared with that of
established RA patients [33]. Interestingly, the SF from these very
early arthritis patients did not contain significant levels of
lactoferrin, with a mean value of 3.0 2.4 g/ml (Fig. 1).
FIG. 1. Lactoferrin levels in RA SF. Lactoferrin concentrations were measured by
ELISA in SFs from patients with RA of >2 yrs (n¼26) (f)o r<3 months (^)
duration (n¼10) and in matched sera from 11 of the patients with established RA
(g). The median value is indicated by a bar.
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We have shown previously that the apoptosis of neutrophils was
inhibited in the synovial microenvironment [5] and that the iron
chelator desferrioxamine could delay neutrophil apoptosis in vitro
[14]. We therefore determined whether lactoferrin, as a naturally
occurring iron chelator present in the inflamed joint, could
modulate neutrophil apoptosis in vitro. Freshly isolated neutro-
phils were cultured with or without iron free lactoferrin at a range
of concentrations and apoptosis was measured by DiOC6 staining
(Fig. 2A) after 9h in culture. Lactoferrin significantly delayed
neutrophil spontaneous apoptosis in a concentration-dependent
manner (Fig. 2A), with significant effects seen at concentrations
50 g/ml (P<0.04) and 100 g/ml (P<0.02). The lactoferrin-
rescued neutrophils were also fully functional, producing a robust
superoxide burst in response to fMLP that was significantly
greater (P<0.01) than neutrophils cultured in medium alone
(Fig. 2B). Lactoferrin alone did not induce superoxide generation
but it did produce a modest increase in CD11b (data not shown),
suggestive of a slight priming effect.
We also determined whether lactoferrin could delay the
apoptosis of neutrophils isolated from RA SF, to ensure that
cells recruited to the joint were still susceptible to lactoferrin
survival signals. Figure 2C shows that neutrophils isolated
from SF entered apoptosis very rapidly with almost 50% loss of
viability after 9h in culture. However, lactoferrin could still
significantly delay their apoptosis (P<0.05). The established
neutrophil survival factor GM-CSF, which is known to be present
in SF, also gave a significant reduction in neutrophil apoptosis
(P<0.05).
Lactoferrin delays neutrophil apoptosis to a similar degree
as pro-inflammatory cytokines
To compare the relative survival promoting effects of lacto-
ferrin with other known neutrophil survival factors we
incubated neutrophils with lactoferrin, GM-CSF, IFN-  and
LPS. Figure 3 shows that GM-CSF was the most potent
neutrophil survival factor (P<0.01) but that lactoferrin was
equivalent to IFN- , achieving 70% of the inhibition seen
with GM-CSF.
The anti-apoptotic effect of RA SF is reduced by removal of
lactoferrin
As the rheumatoid synovial environment contains several
potential neutrophil survival factors it was important to establish
the relative contribution made by lactoferrin. SFs from seven
patients with established RA, with lactoferrin levels ranging from
6.11 to 65.82 g/ml, were treated with either a monoclonal
antibody to lactoferrin (Lactoferrin depletion), or an isotype-
matched control antibody (mock depletion) and incubated with
peripheral blood neutrophils and apoptosis determined. Depletion
of lactoferrin was confirmed by ELISA and was below the
detection limit of the assay at <1ng/ml (data not shown). Figure 4
shows that mock-depleted RA SF significantly delayed neutrophil
apoptosis, from the level of 56% seen in the untreated neutrophils
to 16–42% in the treated cells. Depletion of lactoferrin reduced
the survival effect of the SF in four out of seven samples
(P<0.03), suggesting that in the majority of samples lactoferrin
contributed significantly to the survival effect of SF on human
neutrophils.
Lactoferrin levels correlate with serum CRP and RF
In RA, lactoferrin accumulates in the SF (Fig. 1), most probably
following its release from activated neutrophils. As the actions
of lactoferrin may result in either pro- or anti-inflammatory
outcomes, we determined if there was any correlation between
lactoferrin levels and markers of inflammation or disease duration
in 24 patients with established RA. There was no correlation
between the age of the patient, the duration of their disease, ESR
or degree of joint erosion (Fig. 5A–D). However, there was a very
FIG. 2. Effect of lactoferrin on neutrophil apoptosis and function. (A) Peripheral
blood neutrophils were incubated with medium alone or with medium containing
iron-free lactoferrin at the concentrations shown and apoptosis measured by
loss of DiOC6 staining after 9h in culture. All incubations also contained 10 g/ml
polymyxin B. Data are mean   S.D.( n¼5) and *P<0.04, **P<0.02. (B)
Neutrophils were incubated with 100 g/ml lactoferrin (LTF) for 20h prior to
stimulation with fMLP and measurement of superoxide generation. Data are
expressed as mean   S.D. of the area under the curve (AUC) per 10
6 viable cells
(n¼3). *P<0.01. (C) Neutrophils isolated from RA synovial fluid were incubated
with medium alone, 50ng/ml GM-CSF or 100 g/ml lactoferrin. Apoptosis was
measured by active caspase 3 staining after 9h in culture. Data are mean   S.D.
(n¼3) and *P<0.05. All data were analysed by Student’s t-test.
FIG. 3. Comparison of lactoferrin effects with known neutrophil survival
factors. Peripheral blood neutrophils were incubated with medium alone (control),
100ng/ml LPS, 800IU/ml IFN- , 50ng/ml GM-CSF, 100 g/ml lactoferrin (LTF)
and apoptosis measured by differential staining and nuclear morphology after 9h in
culture. Data are mean   S.D.( n¼5) and were analysed by ANOVA followed by
Dunnett’s comparison with control. *P<0.05, **P<0.01.
Lactoferrin inhibits neutrophil apoptosis 41significant positive correlation between serum CRP levels and
synovial lactoferrin levels (P¼0.008; Fig. 5E). Interestingly, there
was also a very striking association between RF positivity and
lactoferrin levels (P¼0.017; Fig. 5F).
Discussion
In this study we report for the first time that the physiological
iron-binding protein lactoferrin was able to delay spontaneous
apoptosis of both peripheral blood and SF neutrophils. This effect
was equivalent to the rescue effect of other known neutrophil
survival factors such as GM-CSF and type 1 IFNs. We confirm
that lactoferrin is present at significant levels in the SF of patients
with established RA, but also show that it was not found
at similar levels in the SF of patients whose disease duration was
<3 months. Furthermore, depletion of lactoferrin from SF
significantly reduced its ability to delay neutrophil apoptosis.
We thus conclude that lactoferrin contributes to the extended life
span of neutrophils within the rheumatoid joint of patients with
established RA, but does not contribute to reduced neutrophil
apoptosis in the very early stages of RA [6].
This observation for the first time suggests that in the early
and late stages of disease different factors are involved in the
regulation of neutrophil survival.
The question of whether lactoferrin is a pro- or anti-
inflammatory factor in vivo is not merely one of scientific
curiosity. Iron often accumulates in the synovium of patients
with RA, but if iron is bound by lactoferrin it cannot react with
superoxide to generate harmful hydroxyl radicals that cause
significant tissue damage in RA. In this context, the presence of
FIG. 4. The anti-apoptotic effect of synovial fluid is reduced by depletion of
lactoferrin. Peripheral blood neutrophils were incubated with medium alone
(control), or with synovial fluid from seven different RA patients which had
been immunodepleted for lactoferrin (LTF) using an anti-lactoferrin monoclonal
antibody (LTF) or mock-depleted using an isotype control immunoglobulin (Mock).
Apoptosis was measured by active caspase 3 staining after 20h in culture. Control
and immunodepleted data were compared using a paired Student’s t-test and
*P<0.03.
FIG. 5. Lactoferrin levels correlate with serum CRP and RF status. Lactoferrin levels were measured in synovial fluid of 24 patients with RA and correlated with (A) age,
(B) disease duration, (C) serum ESR, (D) presence of joint erosion, (E) serum CRP and (F) seropositivity for RF. Data were analysed by Spearman’s correlation.
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been injected intra-articularly in animal models of inflammation
and has been shown to suppress inflammation modestly [24, 34],
leading to proposals that local administration of lactoferrin may
be useful in the treatment of RA [24]. However, lactoferrin also
promotes neutrophil adhesion [26], which could lead to increased
recruitment and retention of neutrophils and our data shown here
also reveal that it was able to significantly extend neutrophil
lifespan and function. Each of these would help to increase the
number of neutrophils infiltrating the inflamed joint and con-
tribute to the persistence of inflammation. In the case of septic
arthritis, it is probable that extension of neutrophil lifespan within
the joint would be beneficial, increasing the bactericidal capacity
of the neutrophil. Indeed, Staphylococcus aureus-induced arthritis
in mice was significantly reduced by local injection of lactoferrin,
whereas CIA was improved only to a modest extent and
histological analysis of inflamed paws revealed extensive inflam-
mation and erosion in control and lactoferrin-treated mice [24].
Lactoferrin may therefore have clinical utility, but we would
suggest that this be restricted to infective arthritis and that its
wider usage in RA cannot be argued with the same confidence
at present.
Analysis of patient clinical history and markers of disease
activity revealed a strong association between lactoferrin levels
and CRP and RF positivity. The former is not surprising as
inflammation will increase neutrophil recruitment to the joint and
lead to release of lactoferrin from neutrophil granules. What these
data do suggest is that the raised level of lactoferrin has not been
able to lead to reduced systemic inflammation and this is in
agreement with animal studies that have shown that the effects of
lactoferrin were localized to the inflamed joint and do not extend
to the periphery [24]. The association with the presence of RF in
the serum is more intriguing. One possible explanation is that
patients positive for RFs and thus a more serological disease
would also have significant levels of immune complexes in their
SF [35]. Immune complexes can induce degranulation of
neutrophils [10, 36], which would then drive further release of
lactoferrin in to the joint.
The ability of the iron chelators to enter neutrophils could
determine their ability to chelate the intracellular labile iron pool
and delay neutrophil spontaneous apoptosis. Desferrioxamine
is a relatively small iron chelating molecule (656.8 Da) that
has been shown to enter cells [37] and delay neutrophil apop-
tosis [14]. Lactoferrin is a large biological iron-binding protein
(78000–80000Da) that cannot enter cells by passive diffusion.
Transferrin is also present in the rheumatoid synovium and has
been shown to enter cells through receptor-mediated endocytosis.
However, transferrin receptors are expressed mainly on prolifer-
ating cells and mature neutrophils do not express this receptor
[38]. In contrast, neutrophils have been reported to express
specific receptors for lactoferrin making receptor-mediated
endocytosis possible [39]. Furthermore, in contrast to transferrin,
lactoferrin can bind iron at much lower pH, allowing lactoferrin
function even within an acidic environment such as the endocytic
vacuoles. Lactoferrin may therefore be the dominant functional
iron chelator in RA SF.
In conclusion, our findings unveil a previously unrecognized
effect of lactoferrin on neutrophil biology. We predict that lacto-
ferrin could play a significant role in the regulation of neutrophil
apoptosis in vivo. High concentrations of lactoferrin have been
found in the rheumatoid joint [18, 23], which might contribute
to a lack of apoptotic neutrophils in SF of patients with long-
standing disease. However, the iron saturation state of lactoferrin
at the site of inflammation will determine outcome and we
propose that its use clinically should be considered only for septic
arthritis in which extension of neutrophil lifespan could enhance
the microbicidal efficacy of infiltrating neutrophils.
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